Nephrocare Health Services IPO Details
MAINBOARD
Nephrocare Health Services IPO opens for subscription on 10 Dec 2025 and closes on 12 Dec 2025. The IPO will be listed on NSE, BSE with the tentative listing date set for 17 Dec 2025.
Nephrocare Health Services IPO price band has been fixed at ₹438 – ₹460 per share.The face value is ₹2 per share with a lot size of 32.
Nephrocare Health Services IPO total issue size comprises 1,89,35,820 shares (aggregating up to ₹871.05 Cr.). This includes a fresh issue of 76,82,718 shares (aggregating up to ₹353.40 Cr.). Offer for Sale consists of 1,12,53,102 shares (aggregating up to ₹517.64 Cr.). Pre-issue shareholding stands at 9,26,50,799, which will increase to 10,03,33,516 post-issue.
Nephrocare Health Services IPO carries a ₹40 (8.7%) GMP, reflecting investor sentiment.
Nephrocare Health Services IPO Lot Size : Retail Minimum is 1 lot (32 shares) amounting to ₹14,720. Retail Maximum is 13 lots (416 shares) amounting to ₹191,360. SHNI Minimum is 14 lots (448 shares) amounting to ₹206,080. SHNI Maximum is 67 lots (2,144 shares) amounting to ₹986,240. BHNI Minimum is 68 lots (2,176 shares) amounting to ₹1,000,960.
The Lead Managers for Nephrocare Health Services IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is IIFL Capital Services Ltd, Nomura Financial Advisory & Securities (India) Pvt Ltd, Ambit Pvt Ltd, ICICI Securities Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Nephrocare Health Services Limited RHP.
Nephrocare Health Services IPO Details
Nephrocare Health Services IPO Subscription
Nephrocare Health Services IPO Application Wise Breakup (Approx)
Nephrocare Health Services IPO Dates
- 10 Dec 2025Opening dateOpen
- 12 Dec 2025Closing dateClose
- 15 Dec 2025Allotment Date Allotment
- 16 Dec 2025Initiation of RefundsRefund
- 16 Dec 2025Credit of SharesCredit
- 17 Dec 2025Listing dateListing
Nephrocare Health Services IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 32 | ₹14,720 |
| Retail Maximum | 13 | 416 | ₹191,360 |
| SHNI Minimum | 14 | 448 | ₹206,080 |
| SHNI Maximum | 67 | 2144 | ₹986,240 |
| BHNI Minimum | 68 | 2176 | ₹1,000,960 |
Nephrocare Health Services IPO Reservation
Promoter Holding
Nephrocare Health Services IPO Valuations
Nephrocare Health Services Financial Information
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,193.68 | 996.46 | 806.02 | 666.23 |
| Total Income | 483.97 | 769.92 | 574.72 | 443.26 |
| Profit After Tax | 14.23 | 67.10 | 35.13 | -11.79 |
| EBITDA | 110.31 | 166.64 | 99.66 | 48.60 |
| NET Worth | 716.06 | 594.21 | 423.55 | 384.73 |
| Reserves and Surplus | 704.14 | 578.68 | 408.57 | 383.50 |
| Total Borrowing | 207.04 | 225.80 | 243.37 | 196.21 |
| Amount in ₹ Crore | ||||
About Nephrocare Health Services IPO
Incorporated in 2010, Nephrocare Health Services Ltd. is a leading provider of comprehensive dialysis care, offering diagnosis, haemodialysis, home and mobile dialysis solutions, and wellness programs. Its operations are supported by an integrated in-house pharmacy model.
Scale and Presence
As of September 30, 2025, the company operated 519 dialysis clinics, including 51 international centers across the Philippines, Uzbekistan, and Nepal. The network includes the world’s largest dialysis clinic in Uzbekistan.
In India, Nephrocare is present in 288 cities across 21 States and 4 Union Territories, with 77.53% of its clinics located in tier II and tier III cities, addressing critical care needs in underserved regions.
Patients and Treatment Capacity
Fiscal 2025:
Patients served: 29,281
Dialysis treatments completed: 2,885,450
Approx. 10% share of the national dialysis patient base
As of September 30, 2025:
Patients served in India: 31,046
Treatments completed in India: 1,591,377
Total dialysis machines: 5,562
Strategic Partnerships
Nephrocare has partnered with several leading hospital chains to operate in-house dialysis centers, including:
Max Super Speciality Hospital, Fortis Escorts Hospitals, Care Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital, and Ruby Hall Clinic.
Strength Of Nephrocare Health Services IPO
- India's and Asia's largest dialysis chain with leadership across our markets.
- Scale coupled with asset-light model driving cost efficiencies and operational excellence.
- Driving clinical excellence and quality through protocols and advanced technology.
- Organic growth augmented by proven track record of acquisitions and integration in India and internationally.
- Patient-centric leadership and seasoned management team backed by marquee investors.
- Driving sustainable dialysis leadership with environmental, social and governance measures.
- Track record of sustainable growth, profitability and return.
Risk Of Nephrocare Health Services IPO
- Our Company and Subsidiaries are involved in certain legal and regulatory proceedings. Any adverse decision in such proceedings may have an adverse effect on our business, financial condition, cash flows and results of operations.
- Our business depends on the strength of our brand and reputation. Failure to maintain and enhance our brand and reputation, and any negative publicity and allegations in the media against us, even if untrue, may adversely affect the brand, reputation and trust in, our services, which could result in a material adverse impact on our business, financial condition, results of operations and prospects.
- We rely on our in-house and third-party information technology systems in providing our services and managing our operations, and any disruption to such systems or networks could adversely affect our business operations, reputation and financial performance.
- We derive a substantial portion of our revenues from clinics located in southern region of India, and any loss of business in such regions could have an adverse effect on our business, results of operations and financial condition.
- We face competition from hospitals and other dialysis service providers. Any adverse effects on our competitive position could result in a decline in our business, revenues, profitability and market share.
- The dialysis services market is subject to certain threats and challenges, which if materialize, may adversely affect our business, results of operations, financial condition and cash flows.
- Our business depends on the demand for dialysis services, which is affected by patient preferences, economic condition, social factors, disposable income and increasing general health awareness of India's general population, which could decline due to a variety of factors.
- The healthcare reimbursement framework in the Philippines is subject to periodic revisions, which may adversely affect our business, results of operations, financial condition and cash flows.
- Annual indexation under our PPP dialysis contract in Uzbekistan may not fully mitigate inflationary and cost escalation risks, thereby adversely affecting our business, results of operations, financial condition and cash flows.
- We are required to furnish bank guarantees and letters of credit as part of our business operations. Our inability to arrange such guarantees or the invocation of such guarantees may adversely affect our cash flows and financial condition.
Objectives Nephrocare Health Services IPO
1. Capital expenditure by the Company for opening new dialysis clinics in India and
2. Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the Company
3. General corporate purposes
Company Contact Details
Nephrocare Health Services Ltd.
5 th Floor, D Block, iLabs Centre,
Plot 18, Software Units Layout,
Survey No. 64, Madhapur, Shaikpet,
Hyderabad, Telangana, 500081
Phone: +91 40 4240 8039
Email: cs@nephroplus.com
Website: http://www.nephroplus.com/